Should I be worried about Mpox (clades I and II)?
- If you are in the affected area moderate
- WHO’s 14 February 2026 assessment puts risk at moderate for men who have sex with men with new or multiple partners, sex workers and others with multiple casual sexual partners. WHO assesses risk as low for the general population without specific risk factors, so the moderate rating does not apply to everyone in an affected area. According to WHO
- If you are elsewhere in the same country or region moderate
- WHO’s 14 February 2026 assessment is moderate for the specified sexual-contact networks and low for the general population without specific risk factors. Being elsewhere in an affected country does not, by itself, place you in the moderate-risk group. According to WHO
- If you are travelling there soon moderate
- The French surveillance bulletin cites WHO’s 14 February 2026 assessment: moderate for people in specified sexual-contact networks, and low for the general population without specific risk factors. This is a risk-group assessment, not a blanket moderate rating for everyone travelling. According to WHO
- Health surveillance in La Réunion. Bulletin of November 13, 2026. agency:fr:sante-publique-france · 13 Nov 2026
- If you are elsewhere in the world moderate
- The French surveillance bulletin cites WHO’s 14 February 2026 assessment of moderate risk for specified sexual-contact networks across countries. WHO assesses risk as low for the general population without specific risk factors; the moderate rating is not a rating for everyone worldwide. According to WHO
- Health surveillance in La Réunion. Bulletin of November 13, 2026. agency:fr:sante-publique-france · 13 Nov 2026
What is happening
Mpox clades I and II continue to circulate internationally following the global outbreak that began in 2022. WHO documented clade Ib community transmission in all WHO regions in December 2025 and said the second international emergency declaration ended on 5 September 2025. Santé publique France’s 20 November 2026 bulletin reports cumulative official figures of 26 imported cases and five locally acquired cases in Réunion; these are not new cases reported that week. October media coverage reported more than 14,000 confirmed cases worldwide during 2026, unverified against the underlying authority statement and not a current November total, while no comparable November global total establishes a worldwide increase. Officials are continuing surveillance, diagnostic testing and genomic characterization, and WHO reported completed contact tracing with no detected secondary cases after two detections of a virus combining genetic elements of clades Ib and IIb.
- Broader transmission of mpox due to clade Ib MPXV – Global situation WHO · 5 Dec 2025
- Health surveillance in La Réunion. Bulletin of November 20, 2026. Santé publique France · 20 Nov 2026
- Over 14,000 mpox cases confirmed worldwide in 2026 TASS (EN) · 19 Oct 2026
- Mpox: recombinant virus with genomic elements of clades Ib and IIb – Global situation WHO · 14 Feb 2026
Who is affected and how it spreads
Mpox is caused by monkeypox virus and can spread from animals to people and between people through close contact. Person-to-person transmission involves contact with lesions, body fluids, contaminated materials or respiratory secretions during close contact. Sexual contact was the main driver of the large 2022 global outbreak, while WHO also documented sustained sexual and non-sexual transmission of clade I in eastern Democratic Republic of the Congo. Severe disease can occur, particularly in young children, pregnant people and people with weakened immune systems.
- Mpox Person-to-Person Transmission-Where Have We Got So Far? A Systematic Review. Europe PMC · 28 Apr 2023
- Pathogenicity and virulence of monkeypox at the human-animal-ecology interface. Europe PMC · 1 Dec 2023
- Mpox - Democratic Republic of the Congo WHO · 14 Jun 2024
- Broader transmission of mpox due to clade Ib MPXV – Global situation WHO · 5 Dec 2025
What we are watching
- Comparable country-level updates showing whether transmission is increasing, rather than cumulative totals alone.
- The scale and clade distribution of transmission in Madagascar, following imported cases reported by Réunion.
- Additional Ib/IIb recombinant infections or evidence of sustained transmission.
- Changes in severe disease, and gaps in vaccination, diagnosis and access to care.
- New WHO, ECDC or CDC risk assessments.
Updates
- · No new figures or changed agency assessment are established compared with the previous version, which already included Réunion’s 20 November bulletin.
- · The Réunion cumulative figures and WHO risk assessment are unchanged from the previous version.
- · The Réunion cumulative figures and WHO risk assessment are unchanged from the previous version.
- · Santé publique France’s 20 November bulletin adds a newer official update for Réunion, reporting the same cumulative figures of 26 imported and five locally acquired cases.
- · No new figures or changed WHO assessment are established since the previous version.
Sources
- Mpox: recombinant virus with genomic elements of clades Ib and IIb – Global situation WHO · 14 Feb 2026
- Health surveillance in La Réunion. Bulletin of November 13, 2026. agency:fr:sante-publique-france · 13 Nov 2026
- Broader transmission of mpox due to clade Ib MPXV – Global situation WHO · 5 Dec 2025
- Health surveillance in La Réunion. Bulletin of November 20, 2026. Santé publique France · 20 Nov 2026
- Over 14,000 mpox cases confirmed worldwide in 2026 TASS (EN) · 19 Oct 2026
- Mpox Person-to-Person Transmission-Where Have We Got So Far? A Systematic Review. Europe PMC · 28 Apr 2023
- Pathogenicity and virulence of monkeypox at the human-animal-ecology interface. Europe PMC · 1 Dec 2023
- Mpox - Democratic Republic of the Congo WHO · 14 Jun 2024